A Randomized Phase 3 Study of Vincristine Dactinomycin Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI Torisel NSC# 683864 IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Recruiting
40 years or below
All
Phase N/A
1 Location

Brief description of study

The purpose of this study is to compare the event-free survival of patients with IR RMS treated with surgery, radiotherapy and VAC alternating with VI (VAC/VI) to that of patients treated with surgery, radiotherapy and VAC/VI plus temsirolimus (TORI).

Detailed description of study

The purpose of this study is to compare the event-free survival of patients with IR RMS treated with surgery, radiotherapy and VAC alternating with VI (VAC/VI) to that of patients treated with surgery, radiotherapy and VAC/VI plus temsirolimus (TORI).

Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: rhabdomyosarcoma
  • Age: 40 years or below
  • Gender: All

Inclusion Criteria
Patients with newly diagnosed RMS of any subtype, except adult-type pleomorphic, based upon institutional histopathologic classification
Patients must have sufficient tissue available for the required biology study
Adequate bone marrow function
Adequate renal function
Adequate liver function
Exclusion Criteria
Patients who have previously received TORI, another mTOR inhibitor, or any other investigational agent
Patients who have received any chemotherapy (excludign steroids) and/or radiation therapy prior to this enrollment
Patients with uncontrolled hyperglycemia
Patients with hyperlipidemia
Sexually active patient of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for at least 3 months after treatment is completed if sexually active with reproductive potential
Pregnant or breastfeeding (lactating)

Updated on 04 Aug 2024. Study ID: 1606423144 (PHO-FALLON-COG-ARST1431)

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team